Benefit Analysis Reqs Are More Work but Revised PSURs Are Better says EFPIA
Recent changes to EU drug risk-benefit reporting rules mean more work for multinational Pharmas but are still an improvement on ‘old-style’ PSURs says EFPIA.
Archives for April 8, 2013
Novartis, Venter Institute Collaborate on New H7N9 Vaccine with CDC
Novartis, the J. Craig Venter Institute, Synthetic Genomics Vaccines and the US CDC are racing to develop a vaccine for the H7N9 influenza virus sweeping through China.
Water Street Invests in CCBR-Synarc Citing Recruitment and Imaging Markets
Private equity firm Water Street has invested an undisclosed sum in clinical trial services group CCBR-Synarc citing opportunities in the patient recruitment and image analysis markets as the key driver for the move.
Africa in Sight as Yusen Enhances its Contract Distribution Footprint
Yusen Logistics says Africa is “a major target area” as it develops its healthcare distribution services.
India Pushes Back Deadline for Barcodes on Primary Drug Packages Again
India’s Directorate General of Foreign Trade (DGFT) has pushed back the deadline again for adopting new barcodes to track pharmaceutical exports by one year.
Janssen Releases Additional Doxil Lot via Alternative Manufacturing Approach
The US FDA has cleared Janssen to release one Lot of Doxil made using an unapproved manufacturing process at Ben Venue's plant to help alleviate shortages.
BMS to Shutter Ex-Amylin Facility - Redundancies Inevitable
Bristol-Myers Squibb says shuttering Amylin’s San Diego facilities will accelerate its diabetes R&D joint venture with AstraZeneca though approximately 300 jobs will be lost.